CHMP recommends Novartis' Rydapt for AML

EMA's CHMP recommended approval of Rydapt midostaurin (CGP 41251, PKC412) from Novartis AG (NYSE:NVS; SIX:NOVN) to treat newly diagnosed acute myelogenous leukemia (AML) with an FMS-like tyrosine kin...